Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Colorcon
Julphar
Teva
Baxter
Deloitte

Generated: July 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,092,828

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,092,828 protect, and when does it expire?

Patent 8,092,828 protects VYXEOS and is included in one NDA.

This patent has seventeen patent family members in thirteen countries.

Summary for Patent: 8,092,828
Title:Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
Abstract: Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers or proliferative disorders.
Inventor(s): Louie; Arthur (Princeton, NJ), Swenson; Christine (Princeton Jct, NJ), Mayer; Lawrence (North Vancouver, CA), Janoff; Andrew (Yardley, PA)
Assignee: Celator Pharmaceuticals, Inc. (Princeton, NJ)
Application Number:12/032,583
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 8,092,828
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 8,092,828

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Celator Pharms VYXEOS cytarabine; daunorubicin POWDER;INTRAVENOUS 209401-001 Aug 3, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial FOR THE TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 8,092,828

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2008216083 ➤ Try a Free Trial
Canada 2678332 ➤ Try a Free Trial
China 101657098 ➤ Try a Free Trial
China 105998046 ➤ Try a Free Trial
Cyprus 1119631 ➤ Try a Free Trial
Denmark 2120568 ➤ Try a Free Trial
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Citi
US Department of Justice
Harvard Business School
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.